Trial Search Results

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have completed a prior EVG+RTV treatment study.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Gilead Sciences

Stanford Investigator(s):


  • Drug: EVG
  • Drug: RTV
  • Drug: ARV regimen


Phase 2


Inclusion Criteria:

   - Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity.

   - Males and females of childbearing potential must agree to utilize effective
   contraception methods.

   - Ability to understand and sign a written informed consent form.

Exclusion Criteria:

   - Females who are pregnant or breastfeeding.

   - Participation in any other clinical trial without prior approval from the Sponsor.

   - Any other clinical condition or prior therapy that, in the opinion of the
   investigator, would make the subject unsuitable for the study.

   - Subjects receiving ongoing therapy with contraindicated drugs.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Debbie Slamowitz
(650) 723-2804
Not Recruiting